Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 20.37M 14.55M 12.62M 11.64M 10.9M 1.39B 20.8M 139M 53.74M 671M 54.61M 53.43M 2.33B P/E Ratio 2024
-5.24x
P/E Ratio 2025 -7.5x
Enterprise Value 20.14M 14.38M 12.48M 11.5M 10.78M 1.38B 20.56M 137M 53.13M 664M 53.99M 52.82M 2.31B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
91.6%
Yield 2024 *
-
Yield 2025 -
1 day-10.00%
1 week+5.88%
Current month+5.88%
1 month-10.00%
3 months-40.00%
6 months-47.06%
Current year-47.06%
1 week 0.09
Extreme 0.09
0.1
1 month 0.07
Extreme 0.07
0.1
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.36
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Date Insider Type Main position Quantity % Market Cap.
06-05Sell

Director

200,000 0.1114%
06-05Sell

Chief Financial Officer

100,000 0.0557%
06-05Sell

Director

500,000 0.2786%
Change 5-day change 1-year change 3-year change Capi.($)
-10.00%+5.88%-52.63%+38.46% 14.55M
+2.16%+3.17%+43.57%+160.28% 1,035B
-0.07%+4.45%+53.50%+48.95% 574B
-0.08%-0.08%+17.37%+62.66% 397B
+0.31%+0.77%+21.19%+15.95% 324B
+1.38%-0.84%+24.59%+16.16% 281B
+0.84%+3.95%+25.05%+35.01% 278B
+0.69%+4.72%-45.14%-47.93% 193B
+4.84%+2.45%+21.33%+61.85% 191B
+3.61%-2.56%+15.16%+61.12% 156B
Average +0.36%+2.10%+12.40%+45.25% 343B
Weighted average by Cap. +1.31%+2.39%+29.50%+73.02%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.34
Net income -1.71M -1.22M -1.06M -975K -914K -117M -1.74M -11.63M -4.5M -56.27M -4.58M -4.48M -196M -3.53M -2.52M -2.19M -2.02M -1.89M -242M -3.61M -24.07M -9.32M -116M -9.47M -9.27M -405M
Net Debt -113K -80.43K -69.79K -64.33K -60.28K -7.7M -115K -767K -297K -3.71M -302K -295K -12.91M -231K -165K -143K -132K -123K -15.76M -235K -1.57M -608K -7.6M -618K -605K -26.42M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
11/06/26 0.0900 $ -10.00% 13,500
10/06/26 0.1000 $ +11.11% 361,865
09/06/26 0.0900 $ 0.00% 28,158
08/06/26 0.0900 $ -5.26% 423,450
05/06/26 0.0950 $ +11.76% 213,166

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!